AU7001596A - Compounds potentiating retinoid - Google Patents

Compounds potentiating retinoid

Info

Publication number
AU7001596A
AU7001596A AU70015/96A AU7001596A AU7001596A AU 7001596 A AU7001596 A AU 7001596A AU 70015/96 A AU70015/96 A AU 70015/96A AU 7001596 A AU7001596 A AU 7001596A AU 7001596 A AU7001596 A AU 7001596A
Authority
AU
Australia
Prior art keywords
hydrogen atom
alkyl group
represents hydrogen
retinoid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70015/96A
Other languages
English (en)
Inventor
Koichi Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7001596A publication Critical patent/AU7001596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thin Film Transistor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU70015/96A 1995-09-21 1996-09-20 Compounds potentiating retinoid Abandoned AU7001596A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP24263995 1995-09-21
JP15058296 1996-06-12
JP7-242639 1996-06-12
JP8-150582 1996-06-12
PCT/JP1996/002709 WO1997011061A1 (en) 1995-09-21 1996-09-20 Compounds potentiating retinoid

Publications (1)

Publication Number Publication Date
AU7001596A true AU7001596A (en) 1997-04-09

Family

ID=26480129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70015/96A Abandoned AU7001596A (en) 1995-09-21 1996-09-20 Compounds potentiating retinoid

Country Status (13)

Country Link
US (3) US5929069A (enExample)
EP (1) EP0906907B1 (enExample)
KR (1) KR100484294B1 (enExample)
CN (1) CN1121395C (enExample)
AT (1) ATE214055T1 (enExample)
AU (1) AU7001596A (enExample)
CA (1) CA2233012A1 (enExample)
DE (1) DE69619711T2 (enExample)
DK (1) DK0906907T3 (enExample)
EA (1) EA002123B1 (enExample)
NO (1) NO981269L (enExample)
TW (1) TW420667B (enExample)
WO (1) WO1997011061A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066106A2 (en) 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
ATE214055T1 (de) * 1995-09-21 2002-03-15 Inst Med Molecular Design Inc Retinoid-potenzierende verbindungen
CA2309331A1 (en) * 1997-11-12 1999-05-20 Institute Of Medicinal Molecular Design, Inc. Agent acting on retinoid receptor
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6869959B1 (en) 1999-04-28 2005-03-22 Institute Of Medicinal Molecular Design Inc. Heterocyclic carboxylic acid derivatives
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
WO2004083413A1 (ja) * 2003-03-20 2004-09-30 Research Foundation Itsuu Laboratory 器官形成方法
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
EP1733722A4 (en) 2004-03-10 2010-07-14 Res Found Itsuu Lab MEMORY FIXING ACCELERATOR
WO2005099759A1 (ja) * 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び／又は治療のための医薬
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
CN101262861B (zh) * 2005-09-09 2011-04-06 有限会社肯菲思 用于预防及/或治疗肠疾病的药物
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
CA2659549C (en) 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008081427A (ja) * 2006-09-27 2008-04-10 R&R Inc 分泌障害性疾患の予防及び／又は治療のための医薬
US7902260B2 (en) * 2007-02-28 2011-03-08 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom
CA2783589A1 (en) 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2695984A1 (en) 2007-08-15 2009-02-19 Research Foundation Itsuu Laboratory Tricyclic amine compound
ES2614498T3 (es) 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
UA99839C2 (ru) 2007-11-06 2012-10-10 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
JP5567573B2 (ja) 2008-09-11 2014-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アリールグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびそれと関連する方法
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
KR101435729B1 (ko) 2009-09-28 2014-09-01 닛뽕소다 가부시키가이샤 함질소 헤테로 고리 화합물 및 그의 염, 그리고 농원예용 살균제
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012112623A2 (en) * 2011-02-14 2012-08-23 Sloan-Kettering Institute For Cancer Research Rxrg modulators for the treatment of cancer
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
CN103304494B (zh) * 2013-06-20 2015-05-27 河北大学 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
KR200489267Y1 (ko) 2018-09-20 2019-05-23 김은진 폭 조절형 옷걸이
KR200490993Y1 (ko) 2019-06-14 2020-02-04 이현봉 구김방지기능을 구비한 바지걸이
CN114702454A (zh) * 2022-03-29 2022-07-05 江西师范大学 5-烷基-11-芳基-5H-二苯并[b,e][1,4]二氮杂卓衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
ATE214055T1 (de) * 1995-09-21 2002-03-15 Inst Med Molecular Design Inc Retinoid-potenzierende verbindungen
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤

Also Published As

Publication number Publication date
CN1202160A (zh) 1998-12-16
CN1121395C (zh) 2003-09-17
KR100484294B1 (ko) 2005-09-09
EP0906907A1 (en) 1999-04-07
KR19990063661A (ko) 1999-07-26
US5929069A (en) 1999-07-27
US6476017B2 (en) 2002-11-05
TW420667B (en) 2001-02-01
US6121256A (en) 2000-09-19
EA199800318A1 (ru) 1998-10-29
EP0906907B1 (en) 2002-03-06
US20010039272A1 (en) 2001-11-08
DE69619711D1 (de) 2002-04-11
EA002123B1 (ru) 2001-12-24
DK0906907T3 (da) 2002-04-22
CA2233012A1 (en) 1997-03-27
DE69619711T2 (de) 2002-10-17
NO981269D0 (no) 1998-03-20
EP0906907A4 (enExample) 1999-04-07
NO981269L (no) 1998-05-20
ATE214055T1 (de) 2002-03-15
WO1997011061A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
AU7001596A (en) Compounds potentiating retinoid
PL334915A1 (en) Pyrrolidine derivatives exhibiting phospholipase a2 inhibiting activity
AU3648393A (en) Depsipeptide derivative, production thereof and use thereof
PT705833E (pt) Derivado de dc-89
DK0807630T3 (da) Heterocykliske forbindelser
TW223637B (enExample)
AU1171897A (en) 1-methylcarbapenem derivatives
AU5715894A (en) Methotrexate derivative
AU623500B2 (en) Carboxylimino benzothiazole derivatives
AU740079C (en) Antirheumatic agents
EP0590681A3 (en) A process for the preparation of aminothiadiazolylacetyl halide derivatives
ES2067388A1 (es) Procedimiento para la produccion de derivados de piroglutamato de configuracion 2,4-cis